МЕСТО АГОНИСТОВ ИМИДАЗОЛИНОВЫХ РЕЦЕПТОРОВ ПРИ ЛЕЧЕНИИ БОЛЬНЫХ АРТЕРИАЛЬНОЙ ГИПЕРТОНИЕЙ

1. Folkow В. Physiological aspect of primary hypertension. Physiol Rev. 1982; 62: 347-504.

2. Julius S., Nesbitt S. Sympathetic overactivity in hypertension: a moving target. Am J Hypertens 1996; 9: 113s-120s.

3. Goldstein D.S. Plasma catecholamines and essential Hypertension: an analytical review. Hypertension 1983; 5: 86-99.

4. Grassi G., Cattaneo B.M., Seravalle G., Lanfranchi A., Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary Hypertension. Hypertension 1998; 31: 68-72.

5. Yamada Y., Miyajima E., Tochikubo O., Matsukawa T., Ishii M. Agerelated changes in muscle sympathetic nerve activity in essential Hypertension. Hypertension 1989; 13: 870-877.

6. Prichard B.N., Graham B.R. The use of moxonidine in the treatment of hypertension. J Hypertens 1997; 15(suppl 1): S47-S55.

7. Emsberger P., Graves M.E., Graff L.M., Zakieh N., Nguyen P., Collins L.A., Westbrooks K.L. and Johnson G.G. II-imidazoline receptors: Definition, characterization, distribution, and transmembrane signaling. Ann NY Acad Sci 1995; 763: 22-42

8. Ernsberger P. The II-Imidazoline Receptor and Its Cellular Signaling Pathways. Ann NY Acad Sci. 1999; 881: 35-53.

9. Van Zwieten H. Modulation of sympathetic outflow by centrally acting antihypertensive drags. Cardiovasc Drags Ther 1996; 10: 283-9.

10. Haxhiu M.A., Dreshaj I., Schafer S.G., Ernsberger P. Selective antihypertensive action of moxonidine is mediated mainly by II-imidazoline receptors in the rostral ventrolateral medulla. J Cardiovasc Pharmacol. 1994; 24(suppl 1): S1-S8.

11. Ramage A.G., Wilkinson S.J. Evidence that different regional sympathetic outflows vary in their severity to the sympathoinhibitory actions of putative 5-HT1A and 2-adrenoceptor agonists in anaesthetized cats. Br. J. Pharmacol. 1989; 98: 1157-1164.

12. Ziegler D., Haxhiu M.A., Kaan E.C., Papp J.G., Ernsberger P. Pharmacology of moxonidine, an II-imidazoline receptor agonist. J Cardiovasc Pharmacol. 1996; 27(suppl 3): S26-S37.

13. Kirch W., Hutt H-J., Plunitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertensive patients. J Clin Pharmacol. 1990; 30: 1088-1095.

14. Mitrovic V., Patyna W., Huting J., Schlepper M. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther. 1991; 5: 967-972.

15. Prell G.D., Martinelli G.P., Holstein G.R., Matulic-Adamic J., Watanabe K.A., Chan S.L., Morgan N.G., Haxhiu M.A., Ernsberger P. Imidazoleacetic acid-ribotide: an endogenous ligand that stimulates imidazol(in)e receptors. Proc Natl Acad Sci USA. 2004 Sep 14; 101(37): 13677-82.

16. Harron D. Clinical pharmacology of imidazolines and related compounds. Fundam Clin. Pharmacol 1992; 6: S41-4.

17. Chan C.K., Head G.A. Relative importance of central imidazoline receptors for antihypertensive effects of moxonidine and rilmenidine. J Hypertens 1996; 14: 855-64.

18. Bamberger C.M., Monig H., Mill G., et al. Growth hormone secretion in response to the new centrally acting antihypertensive agent moxonidine in normal human subjects: comparison to clonidine and GHRH. Exp Clin Endocrinol Diabetes 1995; 103: 205-8.

19. Reaven G.M. Role of insulin resistance in human disease. Diabets 1998; 37: 1596-1607.

20. Апарина Т.В., Бритов А.Н., Дилакян Э.А., Метельская В.А., Гомазков О.А. Значение исходного уровня активности ангиотензин превращающего фермента у больных с метаболическим синдромом при назначении ингибиторов АПФ и агонистов имидазолиновьгх рецепторов. // Российский кардиологический журнал. 2001. № 11. С. 53-57.

21. Haxhiu M.A., Dreshaj I.A., McFadden C.B., et al. Moxonidine acting centrally inhibits airway reflex responses. Ann NY Acad. Sci. 1999; 881: 372-82.

22. Хирманов В.Н. Альбарел (рилменидин) - селективный агонист имидазолиновьгх рецепторов I1. Фармакологические свойства и опыт клинического применения. // Тер. архив. 2003. № 2. C. 85-88.

23. Neumann Jutta, Gerry Ligtenberg, Liam Oey, Hein A. Koomans and Peter J. Blankestijn, Moxonidine Normalizes Sympathetic Hyperactivity in Patients with Eprosartan-Treated Chronic Renal Failure. J Am Soc Nephrol. 2004; 15: 2902-2907.

24. Koomans A., Peter J. Blankestijn and Jaap A. Joles, Sympathetic Hyperactivity in Chronic Renal Failure: A Wake-up Call Hein. J Am Soc Nephrol. 2004; 15: 524-537.

25. Минушкина Л.О., Затейщиков Д.А., Сидоренко Б.А. Агонисты имидазолиновьгх рецепторов: применение в клинической практике. // Фарматека. 2002. № 7/8. C. 42-47.

26. Genissel P., Bromet N. Pharmacokinetics of rilmenidine. Am J Med 1989; 87: S18-23.

27. Messerli F. Moxonidine: a new and versatile antihypertensive drug. J Cardiovasc Pharmacol 2000; 35: S53-6.

28. Szabo B., Bock C., Nordheim U., et al. Mechnism of the sympaticoinhibition produced by the clonidine-like drags rilmenidine and moxonidine. Ann NY Acad Sci 1999; 881: 253-64.

29. Trimarco B., Morisco C., Sarno D., et al. Rilmenidine in patients with left ventricular hypertrophy: beyond the reduction of left ventricular mass. J Cardiovasc Pharmacol 1995; 26(S2): 29-33.

30. Dikstein K., Manhenke C., Aarsland T., et al. The effect of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure. Int J Cardiol, 2000, 75: 167-76.

31. Coats A. Heart Failure 99 -the MOXCON story. Int J Cardiol. 1999; 71: 109-11.

32. Pocock S., Wilhelmsen L., Dickstein K., Francis G., Wittes J. The data monitoring experience in the MOXCON trial. Eur Heart J. 2004; 25(22): 1974-8.

33. Conn J.N., Pfeffer M.A., Rouleau J., Sharpe N., Swedberg K., Straub M., Wiltse C., Wright T.J. MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003; 5(5): 659-67.

34. Doggrell S.A. Moxonidine: some controversy. Expert Opin Pharmacother. 2001; 2(2): 337-50.

35. Wolk R. Anti-arrhythmic properties of moxonidine-implications for the MOXCON study. Int J Cardiol. 2000 Jun 12; 74(l): 89-92.

36. Swedberg K., Bristow M.R., Cohn J.N., et al. Moxonidine Safety and Efficacy (MOXSE) Investigators Effects of Sustained-Release Moxonidine, an Imidazoline Agonist, on Plasma Norepinephrine in Patients with Chronic Heart Failure Circulation. 2002; 105: 1797.

37. Fauvel J.P., Najem R., Ryon B., et al. Effects of rilmenidine on stress-induced peak blood pressure and renal function. J Cardiovasc Pharmacol 1999; 34: 41-5.